Earnings calls

Zim Laboratories concall ledger

Every earnings call for ZIMLAB — management tone, guidance, KPIs and promise tracking, quarter by quarter.

ZIMLAB · 5 transcripts · Healthcare · latest Q4 FY26

Q4 FY26Published 20 May 2026Call held 20 May 2026

ZIMLAB Q4 FY26 Earnings Call Transcript & Analysis

EBITDA134 millionEBITDA Margin12.7%PAT37 million

EBITDA (Q4 FY26) 134 million; EBITDA Margin (Q4 FY26) 12.7%; PAT (Q4 FY26) 37 million. EU GMP remediation substantially complete with positive re-inspection outcome expected.

Read full transcript & analysis

Q3 FY26Published 13 Feb 2026Call held 13 Feb 2026

ZIMLAB Q3 FY26 Earnings Call Transcript & Analysis

EBITDA145 millionEBITDA Margin13.4%

EBITDA (Q3 FY26) 145 million; EBITDA Margin (Q3 FY26) 13.4%. Operating income of INR 1,087 million in Q3 FY26, showing sequential and YoY improvement.

Read full transcript & analysis

Q2 FY26Published 17 Nov 2025Call held 17 Nov 2025

ZIMLAB Q2 FY26 Earnings Call Transcript & Analysis

EBITDA78 millionEBITDA Margin8.8%PAT-4 million

EBITDA 78 million; EBITDA Margin 8.8%; PAT -4 million. Total operating income at INR887 million, up 23.6% QoQ.

Read full transcript & analysis

Q1 FY26Published 12 Aug 2025Call held 12 Aug 2025

ZIMLAB Q1 FY26 Earnings Call Transcript & Analysis

EBITDA57 million−37% YoYEBITDA Margin7.9%PAT-19 millionPAT Margin-2.6%

EBITDA 57 million (−37% YoY); EBITDA Margin 7.9%; PAT -19 million. Total operating income declined 12.3% YoY to INR718 million.

Read full transcript & analysis

Q4 FY25Published 22 May 2025Call held 22 May 2025

ZIMLAB Q4 FY25 Earnings Call Transcript & Analysis

EBITDA₹16.3 cr−5% YoYEBITDA Margin15%PAT₹4.9 cr−40% YoYPAT Margin4.5%

EBITDA ₹16 cr (−5% YoY); EBITDA Margin 15.0%; PAT ₹5 cr (−40% YoY). FY25 Total Operating Income grew 3.2% YoY to INR 379 crores.

Read full transcript & analysis